Zydus Lifesciences

Global Healthcare Cost Containment Will Erode Premium Margins

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Consensus Narrative from 30 Analysts

Published

18 Nov 24

Updated

14 Aug 25

AnalystConsensusTarget's Fair Value

₹983.73

0.5% overvalued

14 Aug

₹988.80

Loading

1Y

-16.7%

7D

5.6%

Author's Valuation

₹983.7

0.5% overvalued

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 10%

Shared on23 Apr 25
Fair value Decreased 0.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.49%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.52%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 1.07%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

₹983.7

0.5% overvalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

5.62%

Pharma revenue growth rate

1.05%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.73%

Calculation

₹42.69b

Earnings '28

x

33.17x

PE Ratio '28

=

₹1.42t

Market Cap '28

₹1.42t

Market Cap '28

/

1.01b

No. shares '28

=

₹1.41k

Share Price '28

₹1.41k Share Price '28

Discounted to 2025 @ 12.73% p.a.

=

₹983.52

Fair Value '25